Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: Relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells

Cancer Research

Volumn 67, Issue 6, 2007, Pages 2439-2447

  Qi, Chen Feng ^a   Zhou, Jeff X ^a   Chang, Hoon Lee ^a   Naghashfar, Zohreh ^a   Xiang, Shao ^a   Kovalchuk, Alexander L ^b   Fredrickson, Torgny N ^a   Hartley, Janet W ^a   Roopenian, Derry C ^c   Davidson, Wendy F ^d   Janz, Siegfried ^b   Morse III, Herbert C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JACKSON LABORATORY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; INTERLEUKIN 6; PRISTANE;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CANCER STAGING; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TRANSLOCATION; GERMINAL CENTER; HISTOPATHOLOGY; IMMUNOBLASTIC LYMPHOMA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; ONCOGENE MYC; PLASMACYTOMA; PRIORITY JOURNAL; SWISS JAMES LAMBERT MOUSE; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM STAGING; PLASMACYTOMA;

EID: 34047272699     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1561     Document Type: Article

References (48)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors. Pathology and genetics. Tumors of haematopoietic and lymphoid tissues. Lyons: IARC Press; 2001.
2. Morse HC III, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002;100:246-58.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
4. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106:1164-74.
5. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100: 9991-6.
6. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
7. Fonseca R., Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
8. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
9. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multile myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987; 87:342-55.
10. Goasguen JE, Zandecki M, Mathiot C, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leukemia Res 1999;23:1133-40.
11. Leleu X, Genevieve F, Guieze R, et al. Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival. Leukemia Res 2005;29:665-71.
12. Warnke RA, Weiss LM, Chan JKC, Cleary ML, Dorfman RF. Atlas of tumor pathology. Tumors of the lymph nodes and spleen. Washington (DC): Armed Forces Institute of Pathology; 1994.
13. L to cause plasma cell neoplasms in mice. J Clin Invest 2004;113: 1763-73.
14. L mice. Leukemia Res 2005;29:435-44.
15. Wanebo HJ, Gallmeier WM, Boyse EA, Old LJ. Paraproteinemia and reticulum cell sarcoma in an inbred strain. Science 1966;154:901-3.
16. Potter M, Wiener F. Plasmacytomagenesis in mice-model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 1992;13:1681-97.
17. Morse HC III, Riblet R, Asofsky R, Weigert M. Plasmacytomas of the NZB mouse. J Immunol 1978; 121:1969-72.
18. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1999; 187:1825-38.
19. Fredrickson TN, Harris AW. Atlas of mouse hematopathology. Amsterdam: Harwood Academic Publishers; 2000.
20. Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 2002;99:1509-14.
21. Zhang JQ, Okumura C, McCarty T, et al. Evidence for selective transformation of autoreactive immature plasma cells in mice deficient in Fasl. J Exp Med 2004; 200:1467-78.
22. Park SS, Kim JS, Tessarollo L, et al. Insertion of C-Myc into IgH induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005;65:1306-15.
23. Kim JS, Han SS, Park SS, McNeil N, Janz S. Plasma cell tumour progression in iMyc(Eμ) gene-insertion mice. J Pathol 2006;209:44-55.
24. Hartley JW, Chattopadhyay SK, Lander MR, et al. Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses. Lab Invest 2000;80:159-69.
25. Kovalchuk AL, Qi CF, Torrey TA, et al. Burkitt lymphoma in the mouse. J Exp Med 2000;192:1183-90.
26. Qi CF, Xiang S, Shin MS, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas. Leukemia Res 2006;30: 153-63.
27. Bayrd ED. The bone marrow on sternal aspiration in multiple myeloma. Blood 1948;3:987-1018.
28. Banks PM, Keller RH, Li CY, White WL. Malignant lymphoma of plasmablastic identify. A neoplasm with both "immunoblastic" and plasma cellular features. Am J Med 1978;64:906-9.
29. Reed M, McKenna RW, Bridges R, Parkin J, Frizzera G, Brunning RD. Morphologic manifestations of monoclonal gammopathies. Am J Clin Path 1982;76:8-23.
30. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985;65:305-10.
31. Zukerberg LR, Ferry JA, Conlon M, Harris NL. Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei. Am J Clin Pathol 1990;93:657-61.
32. Campo E, Miquel R, Krenacs L, Sorbara L, Raffeld M, Jaffe ES. Primary nodal marginal zone lymphomas of splenic and malt type. Am J Surg Pathol 1999;23:59-68.
33. Hussong JW, Perkins SL, Schnitzer B, Hargreaves H, Frizzera G. Extramedullary plasmacytoma - a form of marginal zone cell lymphoma? Am J Clin Pathol 1999; 111:111-6.
34. Kojima M, Nakamura S, Shimizu K, et al. Nodal arginal zone B-cell lymphoma resembling plasmacytoma arising from a plasma cell variant of localized Castleman's disease: a case report. Acta Pathol Microbiol Immunol Scand 2002;110:523-7.
35. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-32.
36. McNeil N, Kim JS, Ried T, Janz S. Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. Genes Chromosomes Cancer 2005;43:137-46.
37. Morse HC III, Pumphrey JG, Potter M, Asofsky R, Murine plasma cells secreting more than one class of immunoglobulin heavy chain. I. Frequency of two or more M-components in ascitic fluids from 788 primary plasmacytomas. J Immunol 1976;117:541-7.
38. Potter M. Antigen-binding myeloma proteins of mice. Adv Immunol 1977;25:141-211.
39. xid gene are resistant to pristane-induced plasmacytomagenesis. Int Immunol 1999;11:1059-64.
40. Maclennan ICM, Toellner KM, Cunningham AF, et al. Extrafollicular antibody responses. Immunol Rev 2003; 194:8-18.
41. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002;2:323-35.
42. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001;13:195-201.
43. Martin F, Kearney JF. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19 and btk. Immunity 2000;12: 29-49.
44. Rosenbaum H, Harris AW, Bath ML, et al. An E μ-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 1990;9:897-905.
45. Holt JM, Robb-Smith AHT. Multiple myeloma: development of plasma cell sarcoma during apparently successful chemotherapy. J Clin Pathol 1973:26:649-59.
46. Falini B, Desolas I, Levine AM, Parker JW, Lukes RJ, Taylor CR. Emergence of B-immunoblastic sarcoma in patients with multiple myeloma - a clinicopathologic study of 10 cases. Blood 1982;59:923-33.
47. Long JC, Aisenberg AC. Richter's syndrome: a terminal complication of chronic lymphocytic leukemia with distinct clinicopathological features. Am J Clin Pathol 1975;63:786-95.
48. Matsui W, Huff CA, Wang OJ, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004;103: 2332-6.